Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain
作者:Jinshan Nan、Jingming Liu、Guifeng Lin、Shanshan Zhang、Anjie Xia、Pei Zhou、Yangli Zhou、Jiahao Zhang、Jinlong Zhao、Shiyu Zhang、Chong Huang、Yifei Wang、Qian Hu、Junxian Chen、Mingli Xiang、Xin Yang、Shengyong Yang
DOI:10.1021/acs.jmedchem.2c01943
日期:2023.3.9
attractive therapeutic strategy for the treatment of inflammatory pain without psychiatric side effects mediated by the cannabinoid receptor CB1. Herein, we report the discovery of 4-(1,2,4-oxadiazol-5-yl)azepan-2-one derivatives as a new class of CB2 agonists. Systematic structure–activity relationship investigations resulted in the identification of the most potent compound 25r. This compound displayed high
选择性地靶向大麻素受体 CB2 是一种有吸引力的治疗策略,用于治疗炎症性疼痛,而没有大麻素受体 CB1 介导的精神副作用。在此,我们报告发现 4-(1,2,4-oxadiazol-5-yl)azepan-2-one 衍生物作为一类新的 CB2 激动剂。系统的构效关系研究导致鉴定出最有效的化合物25r。该化合物显示出 CB2 对 CB1 的高选择性(CB2 EC 50 = 21.0 nM,E max = 87%,CB1 EC 50 > 30 μM,比率 CB1/CB2 > 1428),具有良好的药代动力学特性。特别是,25r在啮齿动物炎症性疼痛的镇痛模型中显示出显着的疗效。所有结果表明,化合物25r可以作为治疗炎症性疼痛的先导化合物,值得进一步深入研究。